Comparison between Infrastructure Development Finance IPO and Vivimed Labs IPO.
Infrastructure Development Finance IPO is a Mainboard Fixed Price IPO proposed to list at BSE, NSE while Vivimed Labs IPO is a Mainboard Fixed Price proposed to list at BSE, NSE.
The total issue size of Infrastructure Development Finance IPO is up to ₹1,372.24 Cr whereas the issue size of the Vivimed Labs IPO is up to ₹17.51 Cr. The final issue price of Infrastructure Development Finance IPO is ₹34.00 per share and of Vivimed Labs IPO is ₹70.00 per share.
| Infrastructure Development Finance IPO | Vivimed Labs IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹29.00 per share | |
| Issue Price (Upper) | ₹34.00 per share | |
| Issue Price (Final) | ₹34.00 per share | ₹70.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 12,00,00,000 shares | 25,01,429 shares |
| Fresh Issue Size (Amount) | up to ₹408.00 Cr | up to ₹17.51 Cr |
| OFS Issue Size | 28,36,00,000 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹964.24 Cr | up to ₹0.00 Cr |
| Issue Size Total | 40,36,00,000 shares | 25,01,429 shares |
| Issue Size Total (Amount) | up to ₹1,372.24 Cr | up to ₹17.51 Cr |
Infrastructure Development Finance IPO opens on Jul 15, 2005, while Vivimed Labs IPO opens on Jul 09, 2005. The closing date of Infrastructure Development Finance IPO and Vivimed Labs IPO is Jul 22, 2005, and Jul 13, 2005, respectively.
Infrastructure Development Finance IPO P/E ratio is , as compared to Vivimed Labs IPO P/E ratio of .
| Infrastructure Development Finance IPO | Vivimed Labs IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 0 | 55.13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 0 | 36.14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 16.10 | 23.14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Infrastructure Development Finance IPO Retail Individual Investors (RII) are offered 14,12,60,000 shares while in Vivimed Labs IPO retail investors are offered 14,12,60,000 shares. Qualified Institutional Buyers (QIB) are offered 20,18,00,000 shares in Infrastructure Development Finance IPO and 0 shares in Vivimed Labs IPO.
| Infrastructure Development Finance IPO | Vivimed Labs IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 20,18,00,000 shares | 0 shares |
| NII | 6,05,40,000 shares | 9,25,000 shares |
| RII | 14,12,60,000 shares | 9,25,000 shares |
| Employee | 0 shares | 50,000 shares |
| Others | ||
| Total | 40,36,00,000 shares | 25,00,000 shares |
Infrastructure Development Finance IPO subscribed in total, whereas Vivimed Labs IPO subscribed .
